RVMD — Revolution Medicines Income Statement
0.000.00%
Last trade - 00:00
- $6.85bn
- $5.00bn
- $11.58m
- 48
- 11
- 96
- 50
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 50 | 43 | 29.4 | 35.4 | 11.6 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 104 | 154 | 217 | 294 | 499 |
Operating Profit | -54.1 | -111 | -188 | -258 | -487 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -52 | -109 | -187 | -249 | -440 |
Provision for Income Taxes | |||||
Net Income After Taxes | -47.7 | -108 | -187 | -249 | -436 |
Net Income Before Extraordinary Items | |||||
Net Income | -47.7 | -108 | -187 | -249 | -436 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -61.9 | -110 | -187 | -249 | -436 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.05 | -2.01 | -2.57 | -3.08 | -3.86 |